[HTML][HTML] Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
JN Jakobsen, E Santoni-Rugiu, M Grauslund… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Background Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.
JN Jakobsen, E Santoni-Rugiu, M Grauslund… - Oncotarget, 2018 - europepmc.org
Background Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
[引用][C] Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
JN Jakobsen, E Santoni-Rugiu, M Grauslund… - Oncotarget, 2018 - cir.nii.ac.jp
Concomitant driver mutations in advanced <i>EGFR</i>-mutated non-small-cell lung cancer
and their impact on erlotinib treatment | CiNii Research CiNii 国立情報学研究所 学術情報 …
and their impact on erlotinib treatment | CiNii Research CiNii 国立情報学研究所 学術情報 …
[HTML][HTML] Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
JN Jakobsen, E Santoni-Rugiu, M Grauslund… - Oncotarget, 2018 - oncotarget.com
Concomitant driver mutations in advanced EGFR -mutated non-small-cell lung cancer and their
impact on erlotinib treatment | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget Home …
impact on erlotinib treatment | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget Home …
Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
JN Jakobsen, E Santoni-Rugiu, M Grauslund… - …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
[PDF][PDF] Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
JN Jakobsen, E Santoni-Rugiu, M Grauslund… - core.ac.uk
Background: Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
[PDF][PDF] Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
JN Jakobsen, E Santoni-Rugiu, M Grauslund… - researchgate.net
Background: Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
JN Jakobsen, E Santoni-Rugiu, M Grauslund… - Oncotarget, 2018 - research.regionh.dk
Background: Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
[PDF][PDF] Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
JN Jakobsen, E Santoni-Rugiu, M Grauslund… - pdfs.semanticscholar.org
Background: Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …
Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
JN Jakobsen, E Santoni-Rugiu, M Grauslund… - Oncotarget, 2018 - oncotarget.com
Concomitant driver mutations in advanced EGFR -mutated non-small-cell lung cancer and their
impact on erlotinib treatment | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget Home …
impact on erlotinib treatment | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget Home …